CLINUVEL Kommuniqué V
CLINUVELs fünftes Nachrichtenkommuniqué für 2021. Bespricht EPP, klinisches Programm, IR-Update und mehr.
Read MoreCLINUVEL Communiqué V
CLINUVEL’s fifth News Communiqué for 2021. Discusses EPP, clinical program, IR update...
Read MoreCLINUVEL’S GROWTH AND EXPANSION - Jefferies London Healthcare Conference
CLINUVEL's Head of Investor Relations, Malcolm Bull, presents to the 2021 Jefferies...
Read MoreResults of Annual General Meeting 2021
In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations...
Read MoreCEO's Address - 2021 Annual General Meeting
2021 CLINUVEL Annual General Meeting address from CEO, Dr Philippe Wolgen
Read MoreCLINUVEL Expands Pharmaceutical Portfolio
Melanocortin drug NEURACTHEL® (ACTH) added for neurological, endocrinological and degenerative disorders
Read MoreStrategic Update III
CLINUVEL PHARMACEUTICALS LTD today released its third Strategic Update.
Read MoreCLINUVEL Adds ACTH to Portfolio
Melbourne, Australia, 08 November 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read MoreCLINUVEL Investor Webinar Released
CLINUVEL PHARMACEUTICALS LTD today announced an Investor Webinar shall be held on...
Read MoreFirst Patient Treated in CLINUVEL DNA Repair Study
Melbourne, Australia, 22 October 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read MoreCLINUVEL Investor webinar
CLINUVEL PHARMACEUTICALS LTD today announced an Investor Webinar shall be held on...
Read MoreAppendix 4G & Corporate Governance Statement
Melbourne, Australia, 08 October 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More